CD40 Ligand/TNFSF5 Antibody (hu5c8 (Ruplizumab)) [mFluor Violet 500 SE]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-75907MFV500
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Block/Neutralize, Flow Cytometry, Western Blot
Label
mFluor Violet 500 SE
Antibody Source
Monoclonal Human IgG1 kappa Clone # hu5c8 (Ruplizumab)
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Human CD40L
Specificity
The antibody binds to CD40L with an IC50 of 0.845 ug/ml.
Clonality
Monoclonal
Host
Human
Isotype
IgG1 kappa
Applications
Application
Recommended Usage
Block/Neutralize
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD40 Ligand/TNFSF5
Alternate Names
CD154, CD40L, CD40LG, gp39, TNFSF5, TRAP
Gene Symbol
CD40LG
Additional CD40 Ligand/TNFSF5 Products
Product Specific Notices
mFluor(TM) is a trademark of AAT Bioquest, Inc. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...